Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of LY2605541 vs insulin glargine as basal insulin in Asian insulin‑naive type 2 diabetes patients
KCT0000946Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Jul 2013; status: recruiting.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0000946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000946.